WJCD  Vol.7 No.11 , November 2017
Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel
Objectives: We sought to study the genetic polymorphisms of ABCB1 gene in post percutaneous coronary intervention (PCI) patients with clopidogrel resistance. Background: Dual antiplatelet therapy (DAPT) is a guideline mandated therapy for patients who undergo PCI. However there exists interindividual variability in drug response to the antiplatelet agents leading to recurrent thrombotic events. Genetic polymorphisms of ABCB1 gene are one among the causes of this interindividual variability. Methods: It is a single center prospective trial and includes221 patients who underwent PCI and were given clopidogrel as a part of DAPT. Platelet reactivity was assessed by grading of platelet activity index (PAI) and considered as high on treatment platelet reactivity (HTPR), i.e., clopidogrel resistance if PAI > 5. Genetic analysis for ABCB1 C-T polymorphism was done by polymerase chain reaction (PCR) and single strand confirmation polymorphism (SSCP) analysis. Results: Amongst 221 patients, 37 (16.7%) patients had ABCB1 C-T polymorphisms. The mean PAI value in these patients was 5.1 ± 3.0, while it was 3.5 ± 2.5 in those patients without ABCB1 C-T polymorphisms (p = 0.004). Compared to patients without HTPR, the occurrence of primary endpoints was not significantly increased in patients with HTPR except for stent thrombosis which was significantly high in patients with HTPR. HTPR was also associated with ABCB1 C-T polymorphisms (p = 0.04), but these polymorphisms did not predict the clinical outcome. Conclusions: There was significant prevalence of ABCB1 C-T polymorphisms in patients with HTPR. However it was not an independent risk factor for clopidogrel resistance and also it did not influence adverse cardiovascular outcomes.

Cite this paper
Madhavi, R. , Rajasekhar, D. , Sarma, P. , Vanajakshamma, V. , Sowjenya, G. , Sreedhar, K. and Kapil, C. (2017) Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel. World Journal of Cardiovascular Diseases, 7, 390-398. doi: 10.4236/wjcd.2017.711037.
[1]   Mohan, V., Deepa, R., Rani, S.S., et al. (2001) Prevalence of Coronary Artery Disease and Its Relationship to Lipids in a Selected Population in South India. Journal of the American College of Cardiology, 38, 682-687.

[2]   Gupta, R., Gupta, V.P., Sarna, M., et al. (2002) Prevalence of Coronary Heart Disease and Risk Factors in an Urban Indian Population: Jaipur Heart Watch-2. Indian Heart Journal, 54, 59-66.

[3]   Kamili, M.A., Dar, I.H., Ali, G., et al. (2007) Prevalence of Coronary Heart Disease in Kashmiris. Indian Heart Journal, 61, 44-49.

[4]   Gupta, A.K., Bharadwaj, A., Ashotra, S., et al. (2002) Feasibility and Training of Multipurpose Workers in Detection, Prevention and Control of Coronary Artery Disease in Apple-Belt of Shimla Hills. South Asian Journal of Preventive Cardiology, 6, 17-22.

[5]   Kumar, R., Singh, M.C., Ahlawat, S.K., et al. (2006) Urbanization and Coronary Heart Disease: A Study of Urban-Rural Differences in Northern India. Indian Heart Journal, 58, 126-130.

[6]   Silber, S., Albertsson, P., Aviles, F., et al. (2005) Guidelines for Percutaneous Coronary Interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. European Heart Journal, 26, 804-847.

[7]   Jaremo, P., Lindahl, T.L., Fransson, S.G. and Richter, A. (2002) Individual Variations of Platelet Inhibition after Loading Doses of Clopidogrel. Journal of Internal Medicine, 252, 233-238.

[8]   Gurbel, P.A., Bliden, K.P., Hiatt, B.L. and O’Connor, C.M. (2003) Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity. Circulation, 107, 2908-2913.

[9]   Muller, I., Besta, F., Schulz, C., Massberg, S., Schonig, A. and Gawaz, M. (2003) Prevalence of Clopidogrel Non-Responders among Patients with Stable Angina Pectoris Scheduled for Elective Coronary Stent Placement. Journal OF Thrombosis and Haemostasis, 89, 783-787.

[10]   Mobley, J.E., Bresee, S.J., Wortham, D.C., Craft, R.M., Snider, C.C. and Carroll, R.C. (2004) Frequency of Nonresponse Antiplatelet Activity of Clopidogrel during Pretreatment for Cardiac Catheterization. American Journal of Cardiology, 93, 456-458.

[11]   Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al. (2004) Platelet Aggregation According to Body Mass Index in Patients Undergoing Coronary Stenting: Should Clopidogrel Loading—Dose Be Weight Adjusted? Journal of Invasive Cardiology, 16, 169-174.

[12]   Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, E.J. (2005) Variability in Platelet Responsiveness to Clopidogrel among 544 Individuals. Journal of the American College of Cardiology, 45, 246-251.

[13]   Silvain, J., Cayla, G., Hulot, J.S., et al. (2012) High On-Thienopyridine Platelet Reactivity in Elderly Coronary Patients: The Senior-Platelet Study. European Heart Journal, 33, 1241-1250.

[14]   Bliden, K.P., Dichiara, J., Lawal, L., et al. (2008) The Association of Cigarette Smoking with Enhanced Platelet Inhibition by Clopidogrel. Journal of the American College of Cardiology, 52, 531-533.

[15]   Breet, N.J., Sluman, M.A., van Berkel, M.A.J.P.J., et al. (2011) Effect of Gender Difference on Platelet Reactivity. Netherlands Heart Journal, 19, 451-457.

[16]   Taubert, D., Von Beckerath, N., Grimberg, G., et al. (2006) Impact of P-Glycoprotein on Clopidogrel Absorption. Clinical Pharmacology & Therapeutics, 80, 486-501.

[17]   Spiewak, M., Malek, L.A., Kostrzewa, G., Kisiel, B., Serafin, A., et al. (2009) Influence of C3435T Multidrug Resistance Gene-1 (MDR-1) Polymorphism on Platelet Reactivity and Prognosis in Patients with Acute Coronary Syndromes. Kardiologia Polska, 67, 827-834.

[18]   Mega, J.L., Close, S.L., Wiviott, S.D., et al. (2010) Genetic Variants in ABCB1, CYP2C19, and Cardiovascular Outcomes following Treatment with Clopidogrel and Prasugrel. The Lancet, 16, 1312-1319.

[19]   Mega, J.L., Simon, T., Collet, J.P., Anderson, J.L., Antman, E.M., Bliden, K., Cannon, C.P., Danchin, N., Giusti, B., Gurbel, P., Horne, B.D., Hulot, J.S., Kastrati, A., Montalescot, G., Neumann, F.J., Shen, L., Sibbing, D., Steg, P.G., Trenk, D., Wiviott, S.D. and Sabatine, M.S. (2010) Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes among Patients Treated with Clopidogrel Predominantly for PCI: A Meta-Analysis. JAMA, 304, 1821-1830.

[20]   Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., Steg, P.G., Ferrieres, J., Danchin, N. and Becquemont, L. (2009) Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. The New England Journal of Medicine, 360, 363-375.